Alkermes plc. (ALKS) stock
ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30213% above fair value
$47.89+1.42 (+3.06%)
Close on Nov 11, 2026Market cap $8.03BP/E 126.0Yield –
Earnings
Alkermes's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 24, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$480.10M
+21.8% on a year earlier
Adjusted EPS, Q3 FY2026
$0.09
$0.49 a year earlier
Latest guidance
Raised
Feb 25, 2026 · 3 items
Quarterly results
Revenue and earnings per share from each of Alkermes's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 24, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 3, 2026before the open | $480.10M | +21.8% | $0.09 | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 28, 2026before the open | $496.00M | +27.0% | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026before the open | – | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026before the open | $384.50M | -10.6% | $0.29 | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 28, 2025before the open | $394.20M | +4.3% | $0.49 | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 29, 2025before the open | $390.70M | -2.1% | $0.52 | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 1, 2025before the open | $306.50M | -12.5% | $0.13 | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 12, 2025before the open | $430.00M | +13.9% | $0.88 | $1.04 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 24, 2024before the open | $378.10M | -0.7% | $0.55 | $0.72 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 24, 2024before the open | $399.10M | -35.4% | $0.55 | $0.72 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 1, 2024before the open | $350.40M | +21.8% | $0.23 | $0.44 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 15, 2024before the open | $377.50M | +23.9% | $0.66 | $0.22 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 25, 2023before the open | $380.90M | +50.9% | $0.28 | $0.64 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 26, 2023before the open | $617.40M | +123.5% | $1.38 | $0.55 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 26, 2023before the open | $287.60M | +3.3% | -$0.25 | $0.01 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 16, 2023before the open | $304.70M | -6.1% | -$0.17 | $0.14 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022before the open | $252.40M | -14.2% | -$0.39 | $0.02 | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 27, 2022before the open | $276.20M | – | -$0.18 | $0.06 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 27, 2022before the open | $278.50M | – | -$0.22 | $0.12 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 16, 2022before the open | $324.50M | – | $0.01 | $0.23 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 27, 2021before the open | $294.10M | – | $0.18 | $0.14 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 28, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 28, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 11, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 29, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Alkermes's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Total RevenuesGAAP | FY2026 | $1.73B – $1.84B | – | New | Feb 25, 2026 |
| EBITDAnon-GAAP | FY2026 | $60.00M – $90.00M | – | New | Feb 25, 2026 |
| EBITDA marginnon-GAAP | FY2026 | 25% | – | New | Feb 16, 2022 |
| non-GAAP net incomenon-GAAP | FY2026 | 30% | – | New | Feb 16, 2022 |
Guidance history
Every forecast Alkermes put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Feb 25, 2026 | EBITDA | FY2026 | $60.00M – $90.00M | New |
| Feb 25, 2026 | Adjusted EBITDA | FY2026 | $370.00M – $410.00M | Raised |
| Feb 25, 2026 | Total Revenues | FY2026 | $1.73B – $1.84B | New |
| Oct 28, 2025 | EBITDA | FY2025 | $270.00M – $290.00M | Lowered |
| Oct 28, 2025 | Adjusted EBITDA | FY2025 | $365.00M – $385.00M | Raised |
| Oct 28, 2025 | Effective Tax Rate | FY2025 | 17% | Reaffirmed |
| Oct 28, 2025 | Cost of Goods Sold | FY2025 | $195.00M – $205.00M | Raised |
| Oct 28, 2025 | R&D Expense | FY2025 | $315.00M – $325.00M | Raised |
| Oct 28, 2025 | SG&A Expense | FY2025 | $675.00M – $705.00M | Raised |
| Oct 28, 2025 | GAAP Net Income | FY2025 | $230.00M – $250.00M | Lowered |
| Oct 28, 2025 | Total Revenues | FY2025 | $1.43B – $1.49B | Raised |
| Oct 28, 2025 | VIVITROL Net Sales | FY2025 | $460.00M – $470.00M | Lowered |
| Oct 28, 2025 | ARISTADA i Net Sales | FY2025 | $360.00M – $370.00M | Lowered |
| Oct 28, 2025 | LYBALVI Net Sales | FY2025 | $340.00M – $350.00M | Lowered |
| Feb 12, 2025 | EBITDA | FY2025 | $215.00M – $245.00M | New |
| Feb 12, 2025 | Adjusted EBITDA | FY2025 | $310.00M – $340.00M | Raised |
| Feb 12, 2025 | Effective Tax Rate | FY2025 | 17% | New |
| Feb 12, 2025 | VIVITROL Net Sales | FY2025 | $440.00M – $460.00M | New |
| Feb 12, 2025 | ARISTADA i Net Sales | FY2025 | $335.00M – $355.00M | Lowered |
| Feb 12, 2025 | LYBALVI Net Sales | FY2025 | $320.00M – $340.00M | Lowered |
| Feb 12, 2025 | Cost of Goods Sold | FY2025 | $185.00M – $205.00M | Lowered |
| Feb 12, 2025 | R&D Expenses | FY2025 | $305.00M – $335.00M | Raised |
| Feb 12, 2025 | SG&A Expenses | FY2025 | $655.00M – $685.00M | Raised |
| Feb 12, 2025 | GAAP Net Income | FY2025 | $175.00M – $205.00M | Lowered |
| Feb 12, 2025 | Total Revenues | FY2025 | $1.34B – $1.43B | New |
| Feb 15, 2024 | EBITDA | FY2024 | $445.00M – $485.00M | New |
| Feb 15, 2024 | Earnings Per Share | FY2024 | $2.80 | New |
| Feb 15, 2024 | Earnings Per Share | FY2024 | $2.14 | New |
| Feb 15, 2024 | Effective Tax Rate | FY2024 | 17% | New |
| Feb 15, 2024 | EBITDA Margin | FY2024 | 30% | Raised |
| Feb 15, 2024 | VIVITROL Net Sales | FY2024 | $410.00M – $430.00M | New |
| Feb 15, 2024 | ARISTADA i Net Sales | FY2024 | $340.00M – $360.00M | Lowered |
| Feb 15, 2024 | LYBALVI Net Sales | FY2024 | $275.00M – $295.00M | Lowered |
| Feb 15, 2024 | Cost of Goods Sold | FY2024 | $230.00M – $250.00M | Lowered |
| Feb 15, 2024 | R&D Expenses | FY2024 | $225.00M – $255.00M | Reaffirmed |
| Feb 15, 2024 | SG&A Expenses | FY2024 | $625.00M – $655.00M | Raised |
| Feb 15, 2024 | GAAP Net Income | FY2024 | $350.00M – $390.00M | Lowered |
| Feb 15, 2024 | Non-GAAP Net Income | FY2024 | $465.00M – $505.00M | New |
| Feb 15, 2024 | Total Revenues | FY2024 | $1.50B – $1.60B | New |
| Feb 16, 2023 | Capital Expenditures | FY2023 | $35.00M – $40.00M | New |
| Feb 16, 2023 | EBITDA margin | FY2024 | 20% | New |
| Feb 16, 2023 | EBITDA margin | FY2025 | 25% | Raised |
| Feb 16, 2023 | Non-GAAP Net Earnings Per Share (Diluted) | FY2023 | $0.00 – $0.23 | New |
| Feb 16, 2023 | GAAP Net Loss per Share | FY2023 | -$1.20 – -$0.96 | New |
| Feb 16, 2023 | non-GAAP net income | FY2024 | 25% | Raised |
| Feb 16, 2023 | non-GAAP net income | FY2025 | 30% | Raised |
| Feb 16, 2023 | Total Revenue | FY2023 | $1.13B – $1.25B | New |
| Nov 2, 2022 | Capital Expenditures | FY2022 | $35.00M – $40.00M | Reaffirmed |
| Nov 2, 2022 | Non-GAAP Earnings Per Share + | FY2022 | $0.15 – $0.33 | Raised |
| Nov 2, 2022 | GAAP Net Loss per Share + | FY2022 | -$1.13 – -$0.95 | Lowered |
| Nov 2, 2022 | VIVITROL Net Sales | FY2022 | $370.00M – $380.00M | Raised |
| Nov 2, 2022 | ARISTADA Net Sales | FY2022 | $300.00M – $310.00M | Lowered |
| Nov 2, 2022 | LYBALVI Net Sales | FY2022 | $88.00M – $95.00M | Lowered |
| Nov 2, 2022 | INVEGA Franchise Royalties* | FY2022 | $115.00M – $120.00M | Raised |
| Nov 2, 2022 | Other revenues | FY2022 | $197.00M – $215.00M | Raised |
| Nov 2, 2022 | Cost of Goods Sold | FY2022 | $220.00M – $230.00M | Raised |
| Nov 2, 2022 | R&D Expenses | FY2022 | $385.00M – $400.00M | Raised |
| Nov 2, 2022 | SG&A Expenses | FY2022 | $590.00M – $605.00M | Raised |
| Nov 2, 2022 | Amortization of Intangible Assets | FY2022 | $35.00M | Lowered |
| Nov 2, 2022 | Interest Expense, Net | FY2022 | $5.00M – $10.00M | Lowered |
| Nov 2, 2022 | Other Expense, Net | FY2022 | $20.00M | Raised |
| Nov 2, 2022 | Income Tax Benefit | FY2022 | $10.00M – $15.00M | Lowered |
| Nov 2, 2022 | GAAP Net Loss | FY2022 | -$185.00M – -$155.00M | Lowered |
| Nov 2, 2022 | Non-GAAP Net Income | FY2022 | $25.00M – $55.00M | Raised |
| Nov 2, 2022 | Total Revenue | FY2022 | $1.07B – $1.12B | Raised |
| Jul 27, 2022 | Capital Expenditures | FY2022 | $35.00M – $40.00M | Reaffirmed |
| Jul 27, 2022 | Non-GAAP Earnings (Loss) Per Share + | FY2022 | $0.09 – $0.27 | Raised |
| Jul 27, 2022 | GAAP Net Loss per Share + | FY2022 | -$1.07 – -$0.88 | Raised |
| Jul 27, 2022 | VIVITROL Net Sales | FY2022 | $365.00M – $385.00M | Raised |
| Jul 27, 2022 | ARISTADA Net Sales | FY2022 | $295.00M – $315.00M | Lowered |
| Jul 27, 2022 | LYBALVI Net Sales | FY2022 | $75.00M – $90.00M | Lowered |
| Jul 27, 2022 | INVEGA Franchise Royalties* | FY2022 | $95.00M – $100.00M | Raised |
| Jul 27, 2022 | Other revenues | FY2022 | $220.00M – $230.00M | Raised |
| Jul 27, 2022 | Cost of Goods Sold | FY2022 | $215.00M – $225.00M | Lowered |
| Jul 27, 2022 | R&D Expenses | FY2022 | $380.00M – $400.00M | Raised |
| Jul 27, 2022 | SG&A Expenses | FY2022 | $575.00M – $605.00M | Raised |
| Jul 27, 2022 | Amortization of Intangible Assets | FY2022 | $35.00M | Lowered |
| Jul 27, 2022 | Interest Expense, Net | FY2022 | $5.00M – $10.00M | Lowered |
| Jul 27, 2022 | Other Expense, Net | FY2022 | $15.00M | Raised |
| Jul 27, 2022 | Income Tax Benefit | FY2022 | $10.00M – $15.00M | Lowered |
| Jul 27, 2022 | GAAP Net Loss | FY2022 | -$175.00M – -$145.00M | Lowered |
| Jul 27, 2022 | Non-GAAP Net Income (Loss) | FY2022 | $15.00M – $45.00M | Raised |
| Jul 27, 2022 | Total Revenue | FY2022 | $1.05B – $1.12B | Raised |
| Feb 16, 2022 | Capital Expenditures | FY2022 | $35.00M – $40.00M | New |
| Feb 16, 2022 | EBITDA 2 margin | FY2025 | 20% | New |
| Feb 16, 2022 | EBITDA margin | FY2026 | 25% | New |
| Feb 16, 2022 | Non-GAAP Loss Per Share + | FY2022 | -$0.18 – $0.00 | New |
| Feb 16, 2022 | GAAP Net Loss per Share + | FY2022 | -$1.29 – -$1.10 | New |
| Feb 16, 2022 | Cost of Goods Sold | FY2022 | $215.00M – $225.00M | Raised |
| Feb 16, 2022 | R&D Expenses | FY2022 | $385.00M – $415.00M | Raised |
| Feb 16, 2022 | SG&A Expenses | FY2022 | $575.00M – $605.00M | Raised |
| Feb 16, 2022 | Amortization of Intangible Assets | FY2022 | $35.00M | Lowered |
| Feb 16, 2022 | Other Expense, Net | FY2022 | $5.00M – $10.00M | Lowered |
| Feb 16, 2022 | Income Tax Benefit | FY2022 | -$15.00M – -$10.00M | Lowered |
| Feb 16, 2022 | GAAP Net Loss | FY2022 | -$210.00M – -$180.00M | Lowered |
| Feb 16, 2022 | Non-GAAP Net Loss | FY2022 | -$30.00M – $0 | New |
| Feb 16, 2022 | non-GAAP net income | FY2024 | 15% – 20% | New |
| Feb 16, 2022 | non-GAAP net income | FY2025 | 25% | New |
| Feb 16, 2022 | non-GAAP net income | FY2026 | 30% | New |
| Feb 16, 2022 | VIVITROL Net Sales | FY2022 | $355.00M – $385.00M | New |
| Feb 16, 2022 | ARISTADA Net Sales | FY2022 | $290.00M – $320.00M | Lowered |
| Feb 16, 2022 | LYBALVI Net Sales | FY2022 | $55.00M – $75.00M | Lowered |
| Feb 16, 2022 | INVEGA Franchise Royalties* | FY2022 | $45.00M – $50.00M | Lowered |
| Feb 16, 2022 | Total Revenue | FY2022 | $1.00B – $1.09B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Alkermes filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Results
- Update
- Update
- Results
- Results
- Update
- Results
- Results
- Update
- Results
See a number that looks wrong?